A Randomised Double-blind Placebo-controlled Phase III Field Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Chinese Participants Aged 12-65 Years With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Latest Information Update: 24 Jul 2025
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic rhinitis; Rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors ALK-Abello
Most Recent Events
- 24 Jul 2025 New trial record